OnCo
ideasIdea

Pet dogs with spontaneous cancer as a bridge before human trials

Dogs get cancers that closely resemble human ones, with real immune systems and years of natural history. Treating them, with owner consent, can test drugs in a way mice cannot.

Comparative oncology trials in client-owned dogs with spontaneous osteosarcoma, lymphoma, bladder cancer and glioma provide outbred, immunocompetent, spontaneously arising tumours with intact microenvironments. The NCI Comparative Oncology Trials Consortium has run such studies and informed human dosing for several agents. Capacity, standardisation and regulatory recognition, rather than concept, limit its use.

Hypothesis
Agents tested in a standardised canine trial before human phase 1 show better prediction of dose-limiting toxicity and biological activity than mouse data alone, reducing early clinical failures.
Rationale
Spontaneous canine tumours share genomics and metastatic behaviour with human counterparts and progress on a compressed timescale, giving survival readouts within one to two years.
What would test it
Run parallel canine and murine studies for five agents entering human development and compare which better predicted human toxicity and pharmacodynamics.
Maturity
early clinical
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks

Connected

6top

Pages like this

not linked directly; found by shared links